Developer docs
API playgroundTry for free, no card

Search company profiles

Pharmexon

Full company profile

uuid000focp

Namestring
Pharmexon
Legal namestring
Pharmexon Consulting s.r.o.
Websiteurl
pharmexon.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Pharmexon Consulting s.r.o. is a Prague-based life sciences consultancy, incorporated in the Czech Republic in 2016 (Company No. 05267846), that provides expert regulatory affairs, pharmacovigilance, safety writing, ex-agency consulting, authoring/technical review, and pharmaceutical translation services to pharmaceutical, biotechnology, and medical device companies across Europe, the UK, North America, and APAC. Its service offering spans the full product lifecycle — from pre-development pathway planning and clinical/non-clinical/CMC consultancy through Marketing Authorisation Applications (national, DCP, MRP, CP), variations, renewals, and post-marketing pharmacovigilance (PSMF, EUQPPV, LQPPV, xEVMPD). The company does not develop proprietary technology platforms; its core "asset" is a bench of senior experts, including former regulators from INFARMED, MHRA, the Estonian State Agency of Medicines, and WHO Medicines Prequalification, with documented representation at EMA committees (CMDh) — a positioning the firm markets as its "4D Approach."

The firm operates a sales-led B2B motion targeting enterprise pharma clients through direct engagement, a dedicated business development contact, conference presence at CPHI Worldwide and BioBridges, a LinkedIn company page, and a monthly Regulatory Intelligence blog. Revenue is generated entirely on a professional services basis — project-based consulting engagements, ongoing PV service contracts, and multi-year retainers — with pricing quoted per project scope and not publicly disclosed. Notable enterprise clients include Polpharma, Italfarmaco Group, Grindex, Remedica Ltd, ProActiona SA, and GL Pharma, several of which describe multi-year relationships and characterize the firm as an extension of their internal regulatory teams. Operational quality is anchored by ISO 9001:2015 (November 2023) and ISO 17100 (February 2023) certifications, and the firm is independently owned by co-founders Parvinder Punia (Head of Regulatory Affairs & Pharmacovigilance) and Laura Nae, with no disclosed external investors, parent company, or M&A activity.

Short descriptiontext

Prague-based life sciences consultancy (founded 2016) providing expert regulatory affairs, pharmacovigilance, safety writing, ex-agency consulting, and pharmaceutical translation services to pharmaceutical, biotech, and medical device companies across Europe, the UK, North America, and APAC.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPrague, Czechia
HQ citystring
Prague
HQ countrystring
Czechia
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regulatory affairs consulting, pharmacovigilance services, medical translation services, pharmaceutical regulatory compliance, drug registration consulting
Industry2 codes
PRIMARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code1 code
  • Other Management Consulting Services541618
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Life Sciences Regulatory Consulting
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Regulatory Affairs Consulting
TypeProfessional Services
Description

Professional consulting services for regulatory strategy, marketing authorisation applications, submission management, and regulatory compliance across EU, FDA, and global markets. Revenue generated through project-based consulting engagements and retainer arrangements.

pharmexon.com
2Pharmacovigilance Services
TypeProfessional Services
Description

Comprehensive PV services including PSMF management, EUQPPV provision, safety database management, and local PV services. Billed as ongoing service contracts or per-project engagements.

pharmexon.com
3Translation Services
TypeProfessional Services
Description

Specialized pharmaceutical and medical translation services including linguistic reviews, harmonization of product information, and artwork/mock-ups creation for regulatory compliance.

pharmexon.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Pricing details1 tier
1Custom project-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing tailored to project scope, complexity, and client requirements. No public pricing tiers available.

pharmexon.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Pharmexon is a life sciences consultancy that delivers expert regulatory affairs, pharmacovigilance, safety writing, authoring and technical review, ex-agency consulting, and pharmaceutical translation services. It supports pharmaceutical, biotech, and medical device companies across the full product lifecycle — from pre-development pathways and compliant documentation through to marketing authorisation applications, post-marketing maintenance, and pharmacovigilance operations across the EU, UK, US, Canada, and APAC markets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Successfully concluded CMDh referral on Day 60 with positive outcome; CMDh initiated guideline revision as result of case
+3 more records
Product overview1 text field

Pharmexon is a life sciences consultancy offering a comprehensive portfolio of regulatory affairs, pharmacovigilance, safety writing, and translation services. The company operates as a service-based consultancy (not a single software product) with distinct service lines including Regulatory Affairs Services (covering MAAs, submissions, variations, renewals), Pharmacovigilance Services (PV systems, EUQPPV, PSMF management), Local PV Services (LQPPV, local monitoring), Safety Writing and Management, Authoring and Technical Review Services, Ex-Agency Consulting Services, and Translation Services. These services work together to support pharmaceutical companies through pre-development, development, registration, and post-marketing lifecycle management of medicines and medical devices.

Product and service1 record
1Regulatory Affairs Services
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large global CRO with dedicated regulatory affairs and pharmacovigilance consulting practices. Overlaps with Pharmexon on MAA submissions, lifecycle management, and PV services, but typically serves larger enterprise pharma clients.

TypeDirect peer
Description

Regulatory compliance, pharmacovigilance, and medical information consultancy serving pharma, biotech, and medical device companies. Comparable to Pharmexon in its consulting-led model and focus on regulatory strategy and lifecycle maintenance.

TypeBroad incumbent
Description

Global CRO offering integrated clinical, regulatory, and pharmacovigilance services at scale. Competes with Pharmexon for regulatory affairs and PV mandates, particularly for mid-to-large pharma running multi-region submissions.

TypeDirect peer
Description

Specialist regulatory affairs, pharmacovigilance, and quality/compliance consultancy for life sciences, with strong ex-agency talent and pan-European coverage. Directly comparable to Pharmexon in scope of services, target mid-cap pharma clients, and ex-regulator positioning.

TypeBroad incumbent
Description

Mid-sized global CRO with regulatory and pharmacovigilance service lines. Overlaps with Pharmexon on regulatory strategy and lifecycle management but generally pairs these with clinical trial execution capabilities Pharmexon does not offer.

TypeDirect peer
Description

Regulatory and clinical development consultancy with deep expertise in EMA, FDA, and global submission strategy. Comparable to Pharmexon in regulatory affairs focus and ex-agency positioning, with overlapping service lines in MAA management and scientific advice.

TypeBroad incumbent
Description

World's largest CRO with regulatory and safety service lines bundled into broader clinical and commercial offerings. Competes with Pharmexon in regulatory affairs and PV but at a vastly larger scale and with technology-enabled delivery.

TypeDirect peer
Description

Specialized regulatory affairs, pharmacovigilance, and quality management consultancy serving small and mid-cap pharma and biotech. Closest functional peer to Pharmexon across MAA submissions, PV systems, and lifecycle management, now scaled globally through Cencora ownership.

9Pharma Assist (Europe)
TypeEmerging player
Description

European regulatory and pharmacovigilance consultancy serving pharma and biotech. Comparable niche focus to Pharmexon on EU MAA management, variations, and PV services for mid-cap clients.

TypeEmerging player
Description

Boutique European regulatory affairs and pharmacovigilance consultancy. Comparable to Pharmexon in its niche focus on EU regulatory strategy and PV services for mid-cap pharma and biotech clients.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharmexon

Life Sciences Regulatory Consultingpharmexon.com

Prague-based life sciences consultancy (founded 2016) providing expert regulatory affairs, pharmacovigilance, safety writing, ex-agency consulting, and pharmaceutical translation services to pharmaceutical, biotech, and medical device companies across Europe, the UK, North America, and APAC.

What Pharmexon does

Pharmexon Consulting s.r.o. is a Prague-based life sciences consultancy, incorporated in the Czech Republic in 2016 (Company No. 05267846), that provides expert regulatory affairs, pharmacovigilance, safety writing, ex-agency consulting, authoring/technical review, and pharmaceutical translation services to pharmaceutical, biotechnology, and medical device companies across Europe, the UK, North America, and APAC. Its service offering spans the full product lifecycle — from pre-development pathway planning and clinical/non-clinical/CMC consultancy through Marketing Authorisation Applications (national, DCP, MRP, CP), variations, renewals, and post-marketing pharmacovigilance (PSMF, EUQPPV, LQPPV, xEVMPD). The company does not develop proprietary technology platforms; its core "asset" is a bench of senior experts, including former regulators from INFARMED, MHRA, the Estonian State Agency of Medicines, and WHO Medicines Prequalification, with documented representation at EMA committees (CMDh) — a positioning the firm markets as its "4D Approach."

The firm operates a sales-led B2B motion targeting enterprise pharma clients through direct engagement, a dedicated business development contact, conference presence at CPHI Worldwide and BioBridges, a LinkedIn company page, and a monthly Regulatory Intelligence blog. Revenue is generated entirely on a professional services basis — project-based consulting engagements, ongoing PV service contracts, and multi-year retainers — with pricing quoted per project scope and not publicly disclosed. Notable enterprise clients include Polpharma, Italfarmaco Group, Grindex, Remedica Ltd, ProActiona SA, and GL Pharma, several of which describe multi-year relationships and characterize the firm as an extension of their internal regulatory teams. Operational quality is anchored by ISO 9001:2015 (November 2023) and ISO 17100 (February 2023) certifications, and the firm is independently owned by co-founders Parvinder Punia (Head of Regulatory Affairs & Pharmacovigilance) and Laura Nae, with no disclosed external investors, parent company, or M&A activity.

Pharmexon firmographics

Firmographics
Name
Pharmexon
Legal name
Pharmexon Consulting s.r.o.
Website
https://pharmexon.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Prague-based life sciences consultancy (founded 2016) providing expert regulatory affairs, pharmacovigilance, safety writing, ex-agency consulting, and pharmaceutical translation services to pharmaceutical, biotech, and medical device companies across Europe, the UK, North America, and APAC.
Ownership category
akta.pro rank

Pharmexon industry classification

Industry
Product category
Life Sciences Regulatory Consulting
NAICS
Other Management Consulting Services (541618)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Regulatory affairs consulting
  • Pharmacovigilance services
  • Medical translation services
  • Pharmaceutical regulatory compliance
  • Drug registration consulting

Where Pharmexon is headquartered

Location

Headquarters

HQ city
Prague
HQ country
Czechia
HQ region
Europe

Offices1 record

Markets served

Pharmexon business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Regulatory Affairs Consulting: Professional consulting services for regulatory strategy, marketing authorisation applications, submission management, and regulatory compliance across EU, FDA, and global markets. Revenue generated through project-based consulting engagements and retainer arrangements.
  2. Pharmacovigilance Services: Comprehensive PV services including PSMF management, EUQPPV provision, safety database management, and local PV services. Billed as ongoing service contracts or per-project engagements.
  3. Translation Services: Specialized pharmaceutical and medical translation services including linguistic reviews, harmonization of product information, and artwork/mock-ups creation for regulatory compliance.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Pharmexon product offering

Product offering

Core offering

Pharmexon is a life sciences consultancy that delivers expert regulatory affairs, pharmacovigilance, safety writing, authoring and technical review, ex-agency consulting, and pharmaceutical translation services. It supports pharmaceutical, biotech, and medical device companies across the full product lifecycle — from pre-development pathways and compliant documentation through to marketing authorisation applications, post-marketing maintenance, and pharmacovigilance operations across the EU, UK, US, Canada, and APAC markets.

Product overview

Pharmexon is a life sciences consultancy offering a comprehensive portfolio of regulatory affairs, pharmacovigilance, safety writing, and translation services. The company operates as a service-based consultancy (not a single software product) with distinct service lines including Regulatory Affairs Services (covering MAAs, submissions, variations, renewals), Pharmacovigilance Services (PV systems, EUQPPV, PSMF management), Local PV Services (LQPPV, local monitoring), Safety Writing and Management, Authoring and Technical Review Services, Ex-Agency Consulting Services, and Translation Services. These services work together to support pharmaceutical companies through pre-development, development, registration, and post-marketing lifecycle management of medicines and medical devices.

Differentiator

Problem solved

Functional benefit

Products and services

  • Regulatory Affairs Services

Quantifiable outcome

  • Successfully concluded CMDh referral on Day 60 with positive outcome; CMDh initiated guideline revision as result of case
  • +3 more outcomes

Companies that use Pharmexon

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Pharmexon technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Pharmexon partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Pharmexon competitors and assessment

Company assessment

Broad incumbents

  • Parexel: Large global CRO with dedicated regulatory affairs and pharmacovigilance consulting practices. Overlaps with Pharmexon on MAA submissions, lifecycle management, and PV services, but typically serves larger enterprise pharma clients.
  • ICON plc: Global CRO offering integrated clinical, regulatory, and pharmacovigilance services at scale. Competes with Pharmexon for regulatory affairs and PV mandates, particularly for mid-to-large pharma running multi-region submissions.
  • Premier Research: Mid-sized global CRO with regulatory and pharmacovigilance service lines. Overlaps with Pharmexon on regulatory strategy and lifecycle management but generally pairs these with clinical trial execution capabilities Pharmexon does not offer.
  • IQVIA: World's largest CRO with regulatory and safety service lines bundled into broader clinical and commercial offerings. Competes with Pharmexon in regulatory affairs and PV but at a vastly larger scale and with technology-enabled delivery.

Direct peers

  • ProPharma Group: Regulatory compliance, pharmacovigilance, and medical information consultancy serving pharma, biotech, and medical device companies. Comparable to Pharmexon in its consulting-led model and focus on regulatory strategy and lifecycle maintenance.
  • Arriello: Specialist regulatory affairs, pharmacovigilance, and quality/compliance consultancy for life sciences, with strong ex-agency talent and pan-European coverage. Directly comparable to Pharmexon in scope of services, target mid-cap pharma clients, and ex-regulator positioning.
  • Voisin Consulting Life Sciences: Regulatory and clinical development consultancy with deep expertise in EMA, FDA, and global submission strategy. Comparable to Pharmexon in regulatory affairs focus and ex-agency positioning, with overlapping service lines in MAA management and scientific advice.
  • PharmaLex (Cencora): Specialized regulatory affairs, pharmacovigilance, and quality management consultancy serving small and mid-cap pharma and biotech. Closest functional peer to Pharmexon across MAA submissions, PV systems, and lifecycle management, now scaled globally through Cencora ownership.

Emerging players

  • Pharma Assist (Europe): European regulatory and pharmacovigilance consultancy serving pharma and biotech. Comparable niche focus to Pharmexon on EU MAA management, variations, and PV services for mid-cap clients.
  • Regulis Consulting: Boutique European regulatory affairs and pharmacovigilance consultancy. Comparable to Pharmexon in its niche focus on EU regulatory strategy and PV services for mid-cap pharma and biotech clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Pharmexon social profiles

Digital presence

Pharmexon compliance and trust

Trust signal

Compliance2 records

Pharmexon financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharmexon leadership team

Management profile

Number of profiles

Profiles5 records

Pharmexon funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharmexon M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmexon

What does Pharmexon do?

Pharmexon is a life sciences consultancy that delivers expert regulatory affairs, pharmacovigilance, safety writing, authoring and technical review, ex-agency consulting, and pharmaceutical translation services. It supports pharmaceutical, biotech, and medical device companies across the full product lifecycle — from pre-development pathways and compliant documentation through to marketing authorisation applications, post-marketing maintenance, and pharmacovigilance operations across the EU, UK, US, Canada, and APAC markets.

Is Pharmexon a public or private company?

Pharmexon is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Pharmexon founded?

Pharmexon was founded in 2016. It employs 11 to 50 people.

Where is Pharmexon based?

Pharmexon is headquartered in Prague, Czechia, in the Europe region.

How does Pharmexon make money?

Three revenue lines are on record. Regulatory Affairs Consulting is the primary driver. The others are pharmacovigilance Services and translation Services.

Who are Pharmexon's main competitors?

Broad incumbents on record are Parexel, ICON plc, Premier Research and IQVIA. Direct peers are ProPharma Group, Arriello, Voisin Consulting Life Sciences and PharmaLex (Cencora). Emerging players are Pharma Assist (Europe) and Regulis Consulting.

Does Pharmexon have an API?

No public API is recorded for Pharmexon.

What industry is Pharmexon in?

Pharmexon's product category is Life Sciences Regulatory Consulting. Its primary akta.pro industry code is HLAGAAAH, Pharmacovigilance, Risk Management & Medical Affairs CROs, with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 541618 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales